Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,336 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07548177RecruitingPhase 2
Combination drug study for advanced soft tissue sarcoma
This study tests two cancer drugs (benmelstobart and anlotinib) together to treat alveolar soft part sarcoma, a rare soft tissue cancer that has spread or cannot be surgically removed. The drugs work by boosting the immune system and blocking tumor blood vessel growth.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07551050Recruiting
Sacituzumab Govitecan for Advanced HER2-Negative Breast Cancer
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07549958RecruitingPhase 1
Gemcitabine with or without Pitavastatin for Advanced Pancreatic Cancer
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
Orange, CaliforniaAges 18 years+ - NCT07539311RecruitingPhase 2
Testing Rina-S for Advanced Gastrointestinal Cancers
This study tests a new drug called Rina-S in people with advanced gastrointestinal cancers (like stomach, colon, or pancreatic cancer) that have spread or cannot be surgically removed. The drug is designed to help slow or stop cancer growth in people whose cancer has gotten worse despite recent treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07538115Recruiting
Better Heart Monitoring During Sedation for Digestive Procedures
This study compares two ways of monitoring your heart and vital signs during a sedated procedure to examine your digestive tract (ERCP). Researchers want to see if more detailed monitoring helps keep you safer during the procedure.
ÇorumAges 18 years+ - NCT07539155RecruitingPhase 1/Phase 2
MMR Vaccine Injection for Advanced Pancreatic Cancer
This trial tests whether injecting an MMR (measles, mumps, rubella) vaccine directly into a pancreatic tumor can help your immune system fight the cancer. You're eligible if your pancreatic cancer cannot be surgically removed after standard chemotherapy and radiation treatment.
Little Rock, ArkansasAges 18 years+ - NCT07536789RecruitingPhase 2
Testing MRG003 for Advanced Liver Cancer After Prior Treatment
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT07519564RecruitingPhase 1
Study of GB18 Injection for Cancer-Related Weight Loss
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07518147RecruitingPhase 3
BL-M05D1 for advanced stomach cancer after first treatment
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT07518979RecruitingPhase 2
EGFR-targeted drug plus immunotherapy for advanced penile cancer
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
Chengdu, SichuanAges 18 years+ - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT07510802RecruitingPhase 1/Phase 2
CAR-NK cells for advanced HER2+ or triple-negative breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Shenzhen, GuangdongAges 18–75 - NCT07511660Enrolling by invitation
Ovarian cell injection for perimenopause symptom relief
This trial tests injecting special cells called Muse cells into the ovaries to help relieve perimenopause symptoms and possibly restore ovarian function. It may help women experiencing irregular periods, hot flashes, sleep problems, mood changes, or trouble thinking clearly.
Monterrey, Nuevo LeónAges 28–70 - NCT07506109RecruitingPhase 2
Study of sintilimab, ipilimumab, cetuximab, and dabrafenib for advanced colorectal cancer
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07505173RecruitingPhase 2
Targeted radiation plus osimertinib for brain metastases from EGFR-mutant lung cancer
This trial tests adding a brain-sparing radiation technique to the targeted therapy drug osimertinib for people with EGFR-mutant lung adenocarcinoma that has spread to the brain and is causing symptoms. The goal is to see if this combination can better control the brain tumors while protecting the hippocampus, a key memory area.
TianjinAges 18–75 - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT06650514RecruitingPhase 2
OMO-103 for advanced osteosarcoma
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
BarcelonaAges 12 years+ - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT07493668RecruitingPhase 2
Fostrox plus Lenvatinib for advanced liver cancer after immunotherapy
This trial tests whether adding the drug Fostrox to the standard drug Lenvatinib works better than Lenvatinib alone for people with advanced liver cancer that has worsened after initial immunotherapy treatment. It is for those who cannot have surgery and have not had more than one prior cancer treatment.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07497919RecruitingPhase 2
Combination therapy for EGFR-positive advanced penile cancer
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
ShanghaiAges Any age - NCT07497308Recruiting
GDF-15 levels and early outcomes after LVAD surgery
This trial looks at a blood marker called GDF-15 in people getting a heart pump (LVAD) to see if it can help predict early recovery or complications. It may help doctors better understand how patients will do after surgery.
Antalya, Please Select:Ages 18 years+ - NCT06770296RecruitingPhase 1
Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Nanjing, JiangsuAges 18–75
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,336 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.